Skip to main content
. 2023 Feb 22;14:993. doi: 10.1038/s41467-023-36637-3

Fig. 6. Drug repurposing for reducing mortality of severe COVID-19 patients.

Fig. 6

a Single-cell populations of bronchoalveolar immune cells in 11 cured and four deceased severe COVID-19 patients, respectively. b The proportions of cell type in (left) and log10 transformed fold changes in deceased over the cured state (right) of the single-cell populations in a. c Pathway enrichment analysis (deceased severe vs. cured severe) for neutrophil, NK cell, T cell, and monocyte, respectively. P-values were determined by two-sided Fisher’s exact test and were adjusted by BH FDR. d The drug scores in the four deceased severe COVID-19 patients and all four patients among top-ranked significant drugs (FDR < 0.05). e The drug candidate rescinnamine and enalapril, their target genes and pathways in the monocyte, NK cell, T cell, and neutrophil, respectively, from severe COVID-19 patients. All labels and their annotations are the same as in Fig. 4f. P-values were determined by two-sided Fisher’s exact test and were adjusted by BH FDR. Source data are provided as a Source Data file.